Insight Molecular Diagnostics Inc. — Director's Dealing 2016

Jan 4, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2015-12-30

Reporting Person: SEGALL JUDITH (Corporate Secretary)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, no par value	29657	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$2.00	2018-11-30	Common Stock (5000)		Direct

Footnotes

F1: 1/48th of the number of options vested and became exercisable at the end of each full month of employment after the date of grant on December 1, 2011.